{
    "Overall_score": {
        "Correlation": 8,
        "Sentiment": 6,
        "Importance": 7,
        "Impact": 6,
        "Duration": 5,
        "Virality": 4,
        "Source_Score": 7,
        "Specificity": 8,
        "Sector_Spread": 3,
        "Tech_Mentions": 5
    },
    "Each_item": [
        {
            "News_content": "Traders Purchase High Volume of Put Options on Celgene $CELG",
            "Correlation": 9,
            "Sentiment": 4,
            "Importance": 6,
            "Impact": 7,
            "Duration": 4,
            "Virality": 5,
            "Source_Score": 6,
            "Specificity": 8,
            "Sector_Spread": 2,
            "Tech_Mentions": 7
        },
        {
            "News_content": "Attorney in space \"ZERO chance Bass IPR ever affects $CELG revlimid sales.\"",
            "Correlation": 8,
            "Sentiment": 8,
            "Importance": 7,
            "Impact": 6,
            "Duration": 6,
            "Virality": 3,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 1,
            "Tech_Mentions": 2
        },
        {
            "News_content": "For instance, no analyst lowered 12-mo price targets for $CELG -- all remain $144 to $150. Earnings/outlook support it.",
            "Correlation": 8,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 5,
            "Duration": 7,
            "Virality": 4,
            "Source_Score": 9,
            "Specificity": 8,
            "Sector_Spread": 3,
            "Tech_Mentions": 3
        }
    ]
}